Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMB-01 in advanced/metastatic GI cancers
NCT05176665Phase 2Recruiting
- Sponsor
- EpimAb Biotherapeutics
- Start
- Oct 2021
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of emb-01 in gastric cancer (GC), hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA) and 1 more, sponsored by EpimAb Biotherapeutics. Primary endpoints: Number of participants with Adverse Events and Serious Adverse Events, Best Overall Response up to 48 months and 14 more. Started Oct 2021; status: recruiting.
02
Drugs
emb-01
03
Conditions
gastric cancer (GC)hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05176665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05176665.